185 related articles for article (PubMed ID: 38213825)
1. Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation.
Li WW; Zhang YM; Shen MZ; Mo XD
Blood Sci; 2024 Jan; 6(1):e00178. PubMed ID: 38213825
[TBL] [Abstract][Full Text] [Related]
2. Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.
Fukuda M; Hattori J; Ohkubo R; Watanabe A; Maekawa S
Clin Drug Investig; 2024 Jun; ():. PubMed ID: 38935253
[TBL] [Abstract][Full Text] [Related]
3. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B
Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
5. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
[TBL] [Abstract][Full Text] [Related]
6. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
7. Letermovir Effectively Prevents Cytomegalovirus Infection in Patients with Aplastic Anemia After Hematopoietic Stem Cell Transplantation: A Real-World Retrospective Cohort Study.
Zhang Y; Chen X; Zhou M; Zhang Y; Chen C; Zhou R; Li Y; Yang F; Xu S; Wang C; Zhou W; Deng T; Pan S; Mo W; Wang S
Infect Dis Ther; 2024 Feb; 13(2):345-359. PubMed ID: 38265628
[TBL] [Abstract][Full Text] [Related]
8. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
Razonable RR
Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
[TBL] [Abstract][Full Text] [Related]
9. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K
Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Safety, and Cost-effectiveness Analysis of Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Qiu Y; Zhang Y; Teng M; Cheng S; Du Q; Yang L; Wang Q; Wang T; Wang Y; Dong Y; Dong H
Transplantation; 2024 Apr; 108(4):1021-1032. PubMed ID: 38049935
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation.
Li PH; Lin CH; Lin YH; Chen TC; Hsu CY; Teng CJ
Ther Adv Hematol; 2021; 12():2040620721998124. PubMed ID: 33747424
[TBL] [Abstract][Full Text] [Related]
12. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong.
Chan TS; Cheng SS; Chen WT; Hsu DC; Chau RW; Kang SH; Alsumali A; Kwong YL
J Med Econ; 2020 Dec; 23(12):1485-1492. PubMed ID: 33155494
[TBL] [Abstract][Full Text] [Related]
14. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; BĂ©nard N; Pahlavan-Grumel G; Cordonnier C
Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
[TBL] [Abstract][Full Text] [Related]
15. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
[TBL] [Abstract][Full Text] [Related]
16. Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study.
Studer U; Khanna N; Leuzinger K; Hirsch HH; Heim D; Lengerke C; Tsakiris DA; Halter J; Gerull S; Passweg J; Medinger M; Gwerder M
Anticancer Res; 2020 Oct; 40(10):5909-5917. PubMed ID: 32988922
[TBL] [Abstract][Full Text] [Related]
17. The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis.
Chuleerarux N; Nematollahi S; Thongkam A; Dioverti MV; Manothummetha K; Torvorapanit P; Langsiri N; Worasilchai N; Plongla R; Chindamporn A; Sanguankeo A; Permpalung N
Clin Microbiol Infect; 2022 Mar; 28(3):332-344. PubMed ID: 34752926
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study.
Nho D; Lee R; Cho SY; Lee DG; Kim EJ; Park S; Lee SE; Cho BS; Kim YJ; Lee S; Kim HJ
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766290
[TBL] [Abstract][Full Text] [Related]
19. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies.
Vyas A; Raval AD; Kamat S; LaPlante K; Tang Y; Chemaly RF
Open Forum Infect Dis; 2023 Jan; 10(1):ofac687. PubMed ID: 36726548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]